^
    2ms
    Leveraging Pillar Biosciences Targeted NGS Panels as a Rapid Front-Line Strategy to Inform and Accelerate the Delivery of Precision Medicine (AMP 2024)
    In this workshop we review the development, validation and clinical implementation of Pillar Biosciences' rapid 21-gene solid tumor & heme panel oncoReveal Nexus by Memorial Sloan Kettering Cancer Center (MSKCC). We will review this assay's concordance with the MSKCC's MSK-IMPACT® panels and discuss how this type of rapid testing can be leveraged by other clinical laboratories as tool to help sub-select and inform which patients should have CGP testing performed.
    Next-generation sequencing
    |
    MSK-IMPACT • oncoReveal™ Nexus